Abiopharma

🔍 REESE DAVID M (Executive)

Company: AMGEN INC (AMGN)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 2,912 shares of Common Stock (Direct)
  Date: 2026-05-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 43,266.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 454 shares of Common Stock at $329.59 per share (Direct)
  Date: 2026-05-06 | Code: F | equity_swap_involved: 0 | shares_owned_after: 42,812.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 19,002 shares of Nqso (Right to Buy) at $329.59 per share (Derivative)
  Date: 2026-05-05 | Code: A | Expires: 2036-05-05 | Exercise: 2027-05-05 | equity_swap_involved: 0 | shares_owned_after: 19,002.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
• F2: These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
• F3: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026.